Onxeo Launches a Rights Issue With Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million)

Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, created by the merger of BioAlliance Pharma and Topotarget in July 2014, announces today in France and in Denmark the launch of a rights issue with shareholder preferential subscription rights for a gross amount of €35.4 million. This amount may be increased to a maximum of €41.6 million upon exercise of all financial instruments giving access to share capital in the Company before November 26, 2014 and of the extension clause. Based on the subscription commitments, the extension clause will be exercised by at least 682,894 shares, increasing the offering size to at least €38.5 million (excluding exercise of financial instruments before November 26, 2014).